PDCD1 and cancer: Immune checkpoint inhibitors have revolutionised cancer immunotherapy and agents targeting programmed cell death protein-1 (PD-1), programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte associated protein-4 (CTLA-4) are approved for use in many solid tumour types [11].